Literature DB >> 18592372

Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer.

Alberto Calabrò1, Tim Beissbarth, Ruprecht Kuner, Michael Stojanov, Axel Benner, Martin Asslaber, Ferdinand Ploner, Kurt Zatloukal, Hellmut Samonigg, Annemarie Poustka, Holger Sültmann.   

Abstract

The involvement of the immune system for the course of breast cancer, as evidenced by varying degrees of lymphocyte infiltration (LI) into the tumor is still poorly understood. The aim of this study was to evaluate the prognostic value of LI in breast cancer samples using microarray-based screening for LI-associated genes. Starting from the observation that most published ER gene signatures are heavily influenced by the LI effect, we developed and applied a novel approach to dissect molecular signatures. Further, a meta-analysis encompassing 1,044 hybridizations showed that LI alone is not sufficient to highlight breast cancer patients with different prognosis. However, for ER positive patients, high LI was associated with shorter survival times, whereas for ER negative patients, high LI is significantly associated with longer survival. Annotation of LI, in addition to ER status, is important for breast cancer patient prognosis and may have implications for the future treatment of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18592372     DOI: 10.1007/s10549-008-0105-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  63 in total

1.  Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer.

Authors:  Sidra Nawaz; Andreas Heindl; Konrad Koelble; Yinyin Yuan
Journal:  Mod Pathol       Date:  2015-02-27       Impact factor: 7.842

2.  APC downregulated 1 inhibits breast cancer cell invasion by inhibiting the canonical WNT signaling pathway.

Authors:  Sung-Gook Cho
Journal:  Oncol Lett       Date:  2017-08-23       Impact factor: 2.967

3.  The Immune Subtypes and Landscape of Squamous Cell Carcinoma.

Authors:  Bailiang Li; Yi Cui; Dhanya K Nambiar; John B Sunwoo; Ruijiang Li
Journal:  Clin Cancer Res       Date:  2019-03-04       Impact factor: 12.531

4.  Germline Features Associated with Immune Infiltration in Solid Tumors.

Authors:  Sahar Shahamatdar; Meng Xiao He; Matthew A Reyna; Alexander Gusev; Saud H AlDubayan; Eliezer M Van Allen; Sohini Ramachandran
Journal:  Cell Rep       Date:  2020-03-03       Impact factor: 9.423

5.  A three-gene model to robustly identify breast cancer molecular subtypes.

Authors:  Benjamin Haibe-Kains; Christine Desmedt; Sherene Loi; Aedin C Culhane; Gianluca Bontempi; John Quackenbush; Christos Sotiriou
Journal:  J Natl Cancer Inst       Date:  2012-01-18       Impact factor: 13.506

Review 6.  Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity.

Authors:  Caroline Jochems; Jeffrey Schlom
Journal:  Exp Biol Med (Maywood)       Date:  2011-04-12

Review 7.  Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy.

Authors:  Christoph Domschke; Andreas Schneeweiss; Stefan Stefanovic; Markus Wallwiener; Joerg Heil; Joachim Rom; Christof Sohn; Philipp Beckhove; Florian Schuetz
Journal:  Breast Care (Basel)       Date:  2016-04-27       Impact factor: 2.860

Review 8.  Stromal biomarkers in breast cancer development and progression.

Authors:  Jenny A Rudnick; Charlotte Kuperwasser
Journal:  Clin Exp Metastasis       Date:  2012-06-10       Impact factor: 5.150

9.  Pathway-based personalized analysis of breast cancer expression data.

Authors:  Anna Livshits; Anna Git; Garold Fuks; Carlos Caldas; Eytan Domany
Journal:  Mol Oncol       Date:  2015-04-29       Impact factor: 6.603

10.  A fuzzy gene expression-based computational approach improves breast cancer prognostication.

Authors:  Benjamin Haibe-Kains; Christine Desmedt; Françoise Rothé; Martine Piccart; Christos Sotiriou; Gianluca Bontempi
Journal:  Genome Biol       Date:  2010-02-15       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.